The estimated Net Worth of Rachel Humphrey is at least $513 Thousand dollars as of 2 March 2018. Dr Humphrey owns over 16,160 units of Black Diamond Therapeutics Inc stock worth over $284,395 and over the last 9 years he sold BDTX stock worth over $0. In addition, he makes $228,888 as Advisor at Black Diamond Therapeutics Inc.
Dr has made over 5 trades of the Black Diamond Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 16,160 units of BDTX stock worth $106,818 on 2 March 2018.
The largest trade he's ever made was exercising 23,840 units of Black Diamond Therapeutics Inc stock on 28 February 2018 worth over $157,582. On average, Dr trades about 7,759 units every 39 days since 2016. As of 2 March 2018 he still owns at least 46,394 units of Black Diamond Therapeutics Inc stock.
You can see the complete history of Dr Humphrey stock trades at the bottom of the page.
Dr. Rachel Wallach Humphrey M.D., Ph.D. is the Advisor at Black Diamond Therapeutics Inc.
As the Advisor of Black Diamond Therapeutics Inc, the total compensation of Dr D at Black Diamond Therapeutics Inc is $228,888. There are 6 executives at Black Diamond Therapeutics Inc getting paid more, with David Epstein having the highest compensation of $3,346,080.
Dr D is 60, he's been the Advisor of Black Diamond Therapeutics Inc since . There are 5 older and 13 younger executives at Black Diamond Therapeutics Inc. The oldest executive at Black Diamond Therapeutics Inc is Robert Ingram, 77, who is the Independent Chairman of the Board.
Rachel's mailing address filed with the SEC is C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE, MA, 02142.
Over the last 5 years, insiders at Black Diamond Therapeutics Inc have traded over $26,407,257 worth of Black Diamond Therapeutics Inc stock and bought 10,796,678 units worth $105,501,601 . The most active insiders traders include Ali Behbahani, Rajeev M. Shah, and Capital Management, L.P.Ra .... On average, Black Diamond Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $899,443. The most recent stock trade was executed by Venture Capital Vi, L.P.Ver... on 28 August 2024, trading 221,600 units of BDTX stock currently worth $1,400,512.
black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
Black Diamond Therapeutics Inc executives and other stock owners filed with the SEC include: